Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412 [Expanded access from profile 700036424].
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 31 Jul 2015
Price : $35 *
At a glance
- Drugs Ficlatuzumab (Primary)
- Indications Ovarian cancer
- Focus Expanded access; Therapeutic Use
- Sponsors AVEO Oncology
- 28 Jul 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 25 Mar 2014 New trial record